SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a dengue vaccine be safe for autoimmune patients? new trial aims to find out
⭐️ VACCINE ⭐️ Recruiting nowThis study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 22, 2026 12:04 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CHT101, which uses specially engineered immune cells (CAR-T cells) to target and attack faulty cells in people with severe lupus that hasn't improved with standard treatments. The trial will enroll 15 participants to check if th…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 23, 2026 19:03 UTC
-
Immune cell therapy takes on tough autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and potentially calm the ove…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 23, 2026 19:02 UTC
-
Immune cell 'Reset' could tame childhood arthritis and lupus
Disease control Recruiting nowThis early-phase trial is testing a new treatment called CAR-NK cells for children with rheumatic diseases like lupus and arthritis that haven't responded to standard therapies. The treatment uses specially engineered immune cells to target and destroy faulty B cells, aiming to c…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
Could a new drug replace steroids for lupus kidney patients?
Disease control Recruiting nowThis Phase 3 trial tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus nephritis without the need for oral steroids. About 196 people with active lupus kidney disease will be randomly assigned to either the obinutuzumab/MMF regim…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
Cord stem cells could tame lupus in early trial
Disease control Recruiting nowThis early study tests whether a single injection of stem cells from donated umbilical cords is safe for people with active lupus. Ten adults will receive the cells plus their usual care. Researchers will monitor side effects and check if the treatment improves kidney function an…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: LiveKidney.Bio • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Could a cancer drug tame lupus in kids?
Disease control Recruiting nowThis early trial tests if blinatumomab, a drug used for certain blood cancers, can help children with severe lupus that hasn't improved with other treatments. Six children will receive two short courses of the drug and be monitored for a year. The main goals are to check safety a…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Mao Jianhua • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
Experimental CAR-T therapy aims to tame lupus, myositis, and ITP
Disease control Recruiting nowThis early-phase study tests a new cell therapy called BZE2204 in 20 people with lupus, myositis, or immune thrombocytopenia (ITP) that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. The main…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New lupus shot shows promise in early trial
Disease control Recruiting nowThis study tests an investigational drug called SG301, given as an injection under the skin, in 120 adults with systemic lupus erythematosus (SLE) whose disease is not well controlled by standard treatments. The goal is to see if SG301 can reduce lupus disease activity better tha…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
Lupus drug continuation trial offers hope for disease control
Disease control Recruiting nowThis study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New shot for lupus enters early human testing
Disease control Recruiting nowThis study tests a new injection, DB-2304, for safety and how the body handles it. It includes healthy volunteers and people with lupus (SLE or CLE). The goal is to check for side effects and see how the drug works in the body.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New cell therapy hopes to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New drug trial aims to tame autoimmune attacks
Disease control Recruiting nowThis early-stage study tests a new medicine, SAR448501/DR-0201, in 62 adults with lupus or rheumatoid arthritis. The goal is to find safe doses and see how the body responds. Participants receive multiple doses and are followed for about 13 months to check for side effects and an…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
New drug VIS171 enters human testing for lupus, hair loss, and kidney disease
Disease control Recruiting nowThis early-stage trial tests a new drug, VIS171, in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care, and …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:01 UTC
-
Engineered immune cells take on lupus in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goals are to check…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
New biologic combo shows promise for lupus kidney patients
Disease control Recruiting nowThis study compares two newer biologic drugs (belimumab and telitacicept) against the standard treatment for lupus-related kidney inflammation. About 50 adults with active lupus nephritis will receive either a biologic plus steroids, standard therapy (mycophenolate mofetil plus s…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New cell therapy targets tough lupus and muscle disease cases
Disease control Recruiting nowThis early-phase study tests a new treatment called LUCAR-G79D in people with lupus or inflammatory muscle disease that has not improved with standard therapies. The treatment uses modified immune cells to target and attack faulty cells. The main goals are to check safety, find t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis study tests a new treatment called CD19 CAR T cells for people with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack faulty immune cells driving the disease. The trial aims to s…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
New 'Smart' drug aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called CC312 in up to 18 adults with autoimmune diseases like lupus or rheumatoid arthritis that haven't responded to standard treatments. CC312 is designed to help the body's immune cells target and destroy faulty B cells tha…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New lupus drug candidate enters human trials
Disease control Recruiting nowThis study tests a new drug called SSGJ-626 in people with systemic lupus erythematosus (SLE). The drug targets a protein on certain immune cells to help control the disease. About 198 adults aged 18 to 70 will receive either the drug or a placebo to check safety and how well it …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New cell therapy aims to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New lupus drug tracked in global real-world study
Disease control Recruiting nowThis study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
Revolutionary In-Body CAR-T therapy targets autoimmune diseases
Disease control Recruiting nowThis early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and dest…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
Could a One-Time cell treatment tame lupus in young patients?
Disease control Recruiting nowThis study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New lupus drug PIT565 enters human safety trials
Disease control Recruiting nowThis early-stage study tests a new drug called PIT565 in about 54 people with active lupus who have not gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Participants will receive increasing doses of the drug and be…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE), a severe form of lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Qihan Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
Lupus trial tests NAD+ booster to tame immune system
Disease control Recruiting nowThis study tests whether a supplement called nicotinamide riboside (NR) can reduce inflammation and improve immune cell function in women with mild-to-moderate lupus. About 78 participants will receive either NR or a placebo for 12 weeks. Researchers will measure changes in immun…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New lupus drug YK012 enters human trials – hope for better disease control
Disease control Recruiting nowThis study tests a new medicine, YK012, in about 189 adults with moderate to severe lupus. The goal is to see if it is safe and can help control the disease. Participants will receive the drug and be monitored for side effects and how well their lupus responds.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Engineered immune cells take on lupus in first human safety trial
Disease control Recruiting nowThis early-stage study is testing a new treatment called universal CD19/20 CAR-T cells for 12 adults with moderate-to-severe lupus that hasn't improved with standard therapies. The main goals are to check safety, find the right dose, and see if the treatment can reduce lupus symp…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New lupus drug cizutamig enters early human safety trials
Disease control Recruiting nowThis early-stage study is testing a new drug called cizutamig in about 47 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body. Participants must have ac…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Experimental immune reset: could a single infusion tame lupus and other autoimmune attacks?
Disease control Recruiting nowThis early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting the immune cells that cause the dama…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called universal CD19/20 CAR-T cells for people with moderate to severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the faulty immune response…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 05, 2026 12:06 UTC
-
Experimental cell therapy aims to tame Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and vasculitis that have not responded to standard treatments. Participants receive a single infusion of these specially engineered cells. The main goal is to che…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC
-
Neck ultrasound could revolutionize heart attack prevention for arthritis patients
Prevention Recruiting nowThis study tests whether using a carotid ultrasound (a neck scan) to detect hidden plaque in arteries can better prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis and lupus. About 1,944 participants aged 50 and older will b…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Instituto de Investigación Marqués de Valdecilla • Aim: Prevention
Last updated Jun 22, 2026 11:59 UTC
-
Lupus drug may harm fertility – can a hormone shot save it?
Knowledge-focused Recruiting nowThis study surveys women under 40 with lupus who are starting a chemotherapy-like drug called cyclophosphamide, which can damage ovaries and cause early menopause. Some of these women also received a hormone drug called GnRHa to protect their ovaries. Researchers will compare the…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 23, 2026 19:16 UTC
-
10,000 lupus patients join online registry to shape future research
Knowledge-focused Recruiting nowThis study is a fully online registry for adults and children with lupus. Participants complete surveys every six months about their symptoms, treatments, and quality of life. The goal is to gather real-world data to help researchers and doctors better understand lupus and improv…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Foundation of America • Aim: Knowledge-focused
Last updated Jun 23, 2026 19:16 UTC
-
Massive lupus registry launches to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a large registry and biorepository of 3,500 adults with systemic lupus erythematosus (SLE), including those with lupus nephritis and neuropsychiatric lupus. Participants will provide clinical data and biospecimens over time, creating a resource for future r…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Research Alliance • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:57 UTC
-
Heart scans aim to spot hidden risks in kids with lupus
Knowledge-focused Recruiting nowThis study looks at 60 children with lupus to find early signs of heart problems using non-invasive ultrasound. The goal is to identify which children are at higher risk for heart issues. No new treatments are being tested.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:55 UTC
-
Lupus patients who failed multiple drugs under observation in new study
Knowledge-focused Recruiting nowThis study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:04 UTC